Navigation Links
Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
Date:2/4/2008

career, he held the position of vice president, Research & Development, Oncology at Daiichi Pharmaceutical Corporation and prior to that served as its executive director and senior director. Before joining Daiichi Pharmaceutical Corporation, Dr. De Jager served in various positions at Rgene Therapeutics, Inc., Perlmmune, Inc. (formerly Akzo-Organon Teknika/Biotechnology Research Institute) and Sanofi Research.

Dr. De Jager has held academic appointments at Memorial Sloan Kettering Cancer Center, the Institut Jules Bordet (Brussels, Belgium), New Jersey Medical School and the University of Texas M.D. Anderson Cancer Center. He has been a principal investigator and served on committees of many cancer organizations, including the European Organization for Research and Treatment of Cancer (EORTC), the Southeastern Cancer Study Group and the Eastern Cooperative Oncology Group. He is the author of more than 180 publications and abstracts and is the recipient of multiple grants and awards for his work in cancer research and development.

Dr. De Jager earned his M.D. and his B.S. in premedical sciences from the Free University of Brussels in Belgium. He completed his internship at Lenox Hill Hospital, his residency in internal medicine at the Mayo Clinic and a fellowship in medical oncology and clinical pharmacology at Memorial Sloan Kettering Cancer Center.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
8. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Access Pharmaceuticals Announces $2.7 Million New Equity
10. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
11. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 MabVax Therapeutics Holdings, Inc. ... that the Company,s lead antibody, HuMab 5B1, will be ... presentations during the upcoming World Molecular Imaging Congress (WMIC) ... 2-5, 2015. Researchers from the Department of Radiology at ... on the use of MabVax,s lead antibody as a ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with Down ... their day. The biotechnology company, located in the Science ... of the best potential therapies yet for people with Down ... " Correction of Down syndrome and Edwards syndrome aneuploidies ... DNA Research . Elixirgen plans to develop this ...
(Date:8/31/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2015 ... on the discovery and development of novel cancer immunotherapies, ... , M.D., Ph.D., as Chief Executive Officer and ... Drs. Wong and Ho join an experienced management team ... company: Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... New Service Helps Customers to Treat More Patients, ... ARAY ), a global leader in the ... begin offering a treatment planning,service to new and ... centers to access a dedicated team of remote ...
... Medical Specialties, a,47-physician oncology practice located in the ... into an agreement to join US Oncology,s,network. Advanced ... in the U.S., "In today,s challenging healthcare ... keep us in the strongest position to continue,delivering ...
... The National Academy of,Sciences (NAS) Council announced ... officer and executive vice president for Monsanto, has,been ... of Science. This,prize is awarded every three years ... significant, beneficial applications in,industry -- in this case, ...
Cached Biology Technology:Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4Advanced Medical Specialties Joins US Oncology Network 2Advanced Medical Specialties Joins US Oncology Network 3National Academy of Sciences Recognizes Monsanto's Chief Technology Officer for Development of Agricultural Biotechnology 2
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... of researchers has found new candidate disease proteins ... of Biochemistry and Biophysics at the Perelman School ... PhD, St. Jude Children,s Research Hospital, and colleagues ... Nature that mutations in prion-like segments of ...
... study led by St. Jude Children,s Research Hospital has discovered ... nerve cells in amyotrophic lateral sclerosis (ALS), also known as ... mutation occurred in both genes and led to the abnormal ... essential role in normal RNA functioning and have also been ...
... An international group of researchers has discovered seven ... with increased risk of age-related macular degeneration (AMD), a ... network of international investigators representing 18 research groups, also ... which is published online in Nature Genetics ...
Cached Biology News:Adding to the list of disease-causing proteins in brain disorders 2Adding to the list of disease-causing proteins in brain disorders 32 new genes linked to amyotrophic lateral sclerosis and related disorders 22 new genes linked to amyotrophic lateral sclerosis and related disorders 3International consortium discovers seven new genomic regions associated with AMD 2International consortium discovers seven new genomic regions associated with AMD 3
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
...
Kit containing positive control DNA all parts of the HIV-1 genome, HIV-1 negative control DNA, Primers SK38, SK39, SK19...
Biology Products: